title: Alogliptin benzoate for the treatment of type 2 diabetes.
abstract: BACKGROUND
  Type 2 diabetes mellitus continues to be a global problem, placing an enormous burden on healthcare systems and resources. Effective treatment options to minimize the effects of hyperglycemia are essential. Most patients eventually need to take multiple drugs to maintain glycemic control, and many antidiabetic drugs are associated with adverse effects, such as hypoglycemia, weight gain or gastrointestinal effects. Dipeptidyl peptidase (DPP)-4 inhibitor is one of the newer classes of oral antidiabetic drug, and alogliptin is the most recently approved drug in this class.
  
  
  METHODS
  This paper reviews the pharmacodynamic and pharmacokinetic properties of alogliptin and the results of clinical trials evaluating its efficacy at improving glycemic control in patients with type 2 diabetes both as monotherapy and in combination with other antidiabetic drugs. The drug's tolerability and safety profiles are also considered.
  
  
  CONCLUSIONS
  Alogliptin is a DPP-4 inhibitor that can help in improving glycemic control in patients with type 2 diabetes, including the elderly. It is generally well tolerated and does not increase the risk of hypoglycemia or weight gain.
authors.affiliation: Kansai Electric Power Hospital, Center for Diabetes, Endocrinology and Metabolism, , 1-7, Fukushima 2-chome, Fukushima-ku, Osaka, 553-0003 , Japan +81 6 6458 5821 ; +81 6 7501 1403 ; seino.yutaka@e2.kepco.co.jp.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Seino
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yabe
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D010880:Piperidines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D010880:Piperidines; D014498:Uracil; C520853:alogliptin